Description
Abacavir Lamivudine, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, is used in combination with other antiretroviral agents for the treatment of HIV-1 infection.
API- Abacavir Lamivudine
Packaging- Tablets
Strength- 600mg/300mg
Abacavir Lamivudine, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, is used in combination with other antiretroviral agents for the treatment of HIV-1 infection.
The recommended dosage of Abacavir Lamivudine for adults and pediatric patients weighing at least 25 kg is one tablet (600mg/300mg) taken orally once daily, along with other antiretroviral agents, with or without food. Prior to prescribing these tablets, assess pediatric patients for their ability to swallow pills.
The most commonly reported side effects due to Abacavir Lamivudine include insomnia, drug hypersensitivity, depression/depressed mood, nausea, headache/migraine, fatigue/malaise, dizziness/vertigo, and diarrhea.
What is Abacavir Lamivudine?
Abacavir lamivudine (Kivexa 600 mg), is a fixed-dose combination antiretroviral medication authorized for the treatment of HIV/AIDS.
What dosage strengths Abacavir Lamivudine is supplied?
Abacavir Lamivudine is supplied in 600mg/300mg dosage strengths.
How is Abacavir Lamivudine administered?
Abacavir Lamivudine is a kind of fixed-dose combination medicine that typically comes in the form of a tablet for oral administration.
What type of drug is Abacavir Lamivudine?
Abacavir Lamivudine specifically is a type of drug called nucleoside reverse transcriptase inhibitors (NRTIs).